Literature DB >> 8533159

Cisplatin and DNA repair in cancer chemotherapy.

D B Zamble1, S J Lippard.   

Abstract

Cisplatin, a DNA-damaging agent, is one of the most widely used anticancer drugs. As with all members of this class of chemotherapeutic compounds, the clinical success of cisplatin is compromised if tumor cells become resistant by various mechanisms, including enhanced DNA repair. In addition to its role in resistance, DNA repair has been linked to the cytotoxic mechanism of cisplatin. DNA damaged by the drug has proved to be a valuable tool for exploring the details of the nucleotide excision repair pathway.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8533159     DOI： 10.1016/s0968-0004(00)89095-7

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN： 0968-0004            Impact factor:   13.807


  111 in total

1.  The effect of chromatin structure on cisplatin damage in intact human cells.

Authors:  N P Davies; L C Hardman; V Murray
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

2.  Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro.

Authors:  Keng-Boon Lee; Dong Wang; Stephen J Lippard; Phillip A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

3.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

4.  RAD18 and RAD54 cooperatively contribute to maintenance of genomic stability in vertebrate cells.

Authors:  Yukiko M Yamashita; Takashi Okada; Takahiro Matsusaka; Eiichiro Sonoda; Guang Yu Zhao; Kasumi Araki; Satoshi Tateishi; Masaru Yamaizumi; Shunichi Takeda
Journal:  EMBO J       Date:  2002-10-15       Impact factor: 11.598

5.  The Rad51 paralog Rad51B promotes homologous recombinational repair.

Authors:  M Takata; M S Sasaki; E Sonoda; T Fukushima; C Morrison; J S Albala; S M Swagemakers; R Kanaar; L H Thompson; S Takeda
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 6.  A copper connection to the uptake of platinum anticancer drugs.

Authors:  John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

7.  Bifunctional binding of cisplatin to DNA: why does cisplatin form 1,2-intrastrand cross-links with ag but not with GA?

Authors:  Yogita Mantri; Stephen J Lippard; Mu-Hyun Baik
Journal:  J Am Chem Soc       Date:  2007-04-03       Impact factor: 15.419

8.  Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.

Authors:  Datong Zheng; Yanping Chen; Caijie Gao; Yongyue Wei; Guochun Cao; Nan Lu; Yayi Hou; Xiuqin Jiang; Jianjun Wang
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

9.  Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity.

Authors:  Danyelle M Townsend; Kenneth D Tew; Lin He; Jarrod B King; Marie H Hanigan
Journal:  Biomed Pharmacother       Date:  2008-09-07       Impact factor: 6.529

10.  Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation.

Authors:  Oscar M Tirado; Caitlin M MacCarthy; Naheed Fatima; Joaquín Villar; Silvia Mateo-Lozano; Vicente Notario
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.